Sparsentan: Completed Phase II enrollment

Retrophin completed enrollment of >100 patients in the double-blind, international Phase II DUET trial

Read the full 140 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE